Back to Search
Start Over
Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson's disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study
- Source :
- The Lancet Neurology, The Lancet Neurology, Elsevier, 2015, 14 (7), pp.693-701. ⟨10.1016/S1474-4422(15)00087-3⟩, The Lancet Neurology, 2015, 14 (7), pp.693-701. ⟨10.1016/S1474-4422(15)00087-3⟩
- Publication Year :
- 2015
- Publisher :
- HAL CCSD, 2015.
-
Abstract
- International audience; Background High-frequency deep brain stimulation (DBS) with a single electrical source is effective for motor symptom relief in patients with Parkinson's disease. We postulated that a multiple-source, constant-current device that permits well defined distribution of current would lead to motor improvement in patients with Parkinson's disease. Methods We did a prospective, multicentre, non-randomised, open-label intervention study of an implantable DBS device (the VANTAGE study) at six specialist DBS centres at universities in six European countries. Patients were judged eligible if they were aged 21–75 years, had been diagnosed with bilateral idiopathic Parkinson's disease with motor symptoms for more than 5 years, had a Hoehn and Yahr score of 2 or greater, and had a Unified Parkinson's disease rating scale part III (UPDRS III) score in the medication-off state of more than 30, which improved by 33% or more after a levodopa challenge. Participants underwent bilateral implantation in the subthalamic nucleus of a multiple-source, constant-current, eight-contact, rechargeable DBS system, and were assessed 12, 26, and 52 weeks after implantation. The primary endpoint was the mean change in UPDRS III scores (assessed by site investigators who were aware of the treatment assignment) from baseline (medication-off state) to 26 weeks after first lead implantation (stimulation-on, medication-off state). This study is registered with ClinicalTrials.gov, number NCT01221948. Findings Of 53 patients enrolled in the study, 40 received a bilateral implant in the subthalamic nucleus and their data contributed to the primary endpoint analysis. Improvement was noted in the UPDRS III motor score 6 months after first lead implantation (mean 13·5 [SD 6·8], 95% CI 11·3–15·7) compared with baseline (37·4 [8·9], 34·5–40·2), with a mean difference of 23·8 (SD 10·6; 95% CI 20·3–27·3; p
- Subjects :
- Adult
Male
Levodopa
medicine.medical_specialty
Deep brain stimulation
Parkinson's disease
medicine.medical_treatment
Deep Brain Stimulation
[SDV]Life Sciences [q-bio]
03 medical and health sciences
0302 clinical medicine
Rating scale
Subthalamic Nucleus
medicine
Clinical endpoint
Humans
Prospective Studies
Prospective cohort study
030304 developmental biology
Aged
0303 health sciences
business.industry
Parkinson Disease
Middle Aged
medicine.disease
3. Good health
Electrodes, Implanted
Subthalamic nucleus
Treatment Outcome
Physical therapy
Female
Neurology (clinical)
Implant
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 14744422 and 14744465
- Database :
- OpenAIRE
- Journal :
- The Lancet Neurology, The Lancet Neurology, Elsevier, 2015, 14 (7), pp.693-701. ⟨10.1016/S1474-4422(15)00087-3⟩, The Lancet Neurology, 2015, 14 (7), pp.693-701. ⟨10.1016/S1474-4422(15)00087-3⟩
- Accession number :
- edsair.doi.dedup.....e49db8ef4d734e302dc2340e77b286f5
- Full Text :
- https://doi.org/10.1016/S1474-4422(15)00087-3⟩